Results 211 to 220 of about 32,846 (250)

Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Alrasheed T, Mostafa MEA, Madkhali MA, Khairy HA.   +3 more
europepmc   +1 more source

Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction, contributing to heightened risk of progressive liver and cardiovascular disease.
Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson   +4 more
wiley   +1 more source

Comparative effectiveness of long-term anti-obesity medications in routine clinical practice: a retrospective cohort study using real-world data. [PDF]

Transl Clin Pharmacol
Kim CG, Koh JM, Bae KS.
europepmc   +1 more source

Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

Obesity Reviews, Volume 27, Issue 4, April 2026.
ABSTRACT Anti‐obesity medications promote greater degrees of weight loss than lifestyle interventions alone. There is an important need to understand whether loss of skeletal muscle during pharmacologically induced weight loss is clinically significant due to its essential role in health and disease.
Arden McMath, Dympna Gallagher
wiley   +1 more source

GLP-1RAs: antidiabetic drug crossover-new hope for chronic inflammatory airway diseases. [PDF]

Respir Res
Chen Y, Shen Y, Shen H, Liu Z.
europepmc   +1 more source

GLP‐1 Receptor Agonists for the Prevention of New‐Onset Heart Failure: A Systematic Review and Meta‐Analysis of Placebo‐Controlled Randomized Clinical Trials

Obesity Reviews, Volume 27, Issue 4, April 2026.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) improve outcomes in heart failure (HF) with preserved ejection fraction. Whether GLP‐1 RA prevent new‐onset HF in Type 2 diabetes or obesity requires further investigation. Methods We performed an updated meta‐analysis of randomized placebo‐controlled trials (RCT) of treatment ...
João Sérgio Neves, Carolina B. Lobato, Ana Rita Leite, Catarina Vale, Francisco Vasques‐Nóvoa, Francisca Saraiva, Adelino Leite‐Moreira, Jens J. Holst, João Pedro Ferreira   +8 more
wiley   +1 more source

Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with type 2 diabetes mellitus: a systematic review and meta-analysis. [PDF]

Front Nutr
Al Qudah J, Beni ND, Ibrahim N, Khader S, Dempsey L, Butler AE.   +5 more
europepmc   +1 more source

Quantitative evaluation of peptide analogue distribution in mouse tissue using 3D computer modelling [PDF]

, 2017
Jensen, Casper Bo
core  

Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). [PDF]

Diabetes Care
Gonzalez JS, Wen H, Butera NM, Uschner D, Krause-Steinrauf H, Gramzinski MR, Wexler DJ, Petrovitch H, Hoogendoorn CJ, Crespo-Ramos G, Presley C, Fattaleh B, Lagari V, Walker EA, Cherrington AL, GRADE Research Group* .   +15 more
europepmc   +1 more source

Weekly Liraglutide for the Management of Intractable Polydipsia and Interdialytic Weight Gain in a Patient on Hemodialysis: A Case Report. [PDF]

Cureus
Mora-Bravo F, Morales PT, Pincay G, Pineda S, Morales B.   +4 more
europepmc   +1 more source